C. Robert Valeri
Research Subjects
Research Interests
C. Robert Valeri has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Gina Ragno
NBRL, Inc. Boston, MA
20 shared publicationsG. Ragno
5 shared publicationsAlbert Giorgio
2 shared publicationsH. Macgregor
From the Naval Blood Research Laboratory, Boston University School of Medicine, Boston, Massachusetts
2 shared publicationsHollace Macgregor
2 shared publicationsL. Summaria
Centeon Corporation, Kanakee, IL, USA
2 shared publications
Latest Publications
- 1 July 2015
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 29 (3) , 205-206
Response to the Article on Dimethyl Sulfoxide–Cryopreserved Platelets Published in Transfusion Medicine Reviews Volume 28(4)
- 1 July 2015
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 29 (3) , 205-206
Response to the Article on Dimethyl Sulfoxide–Cryopreserved Platelets Published in Transfusion Medicine Reviews Volume 28(4)
- 30 April 2012
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 46 (2) , 121-123
The unrecognized effects of the volume and composition of the resuscitation fluid used during the administration of blood products
- 30 April 2012
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 46 (2) , 121-123
The unrecognized effects of the volume and composition of the resuscitation fluid used during the administration of blood products
- 29 October 2010
- Published by Wiley in Transfusion
- Vol. 50 (11) , 2506
To the Editor
- 29 October 2010
- Published by Wiley in Transfusion
- Vol. 50 (11) , 2504
To the Editor
- 1 June 2010
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 42 (3) , 223-233
An approach to prevent the severe adverse events associated with transfusion of FDA-approved blood products
- 1 June 2010
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 42 (3) , 223-233
An approach to prevent the severe adverse events associated with transfusion of FDA-approved blood products
- 1 May 2010
- Published by Elsevier in Journal of Surgical Research
- Vol. 160 (1) , 169-177
Quiescent Platelets Stimulate Angiogenesis and Diabetic Wound Repair
- 1 May 2010
- Published by Elsevier in Journal of Surgical Research
- Vol. 160 (1) , 169-177
Quiescent Platelets Stimulate Angiogenesis and Diabetic Wound Repair
- 31 December 2008
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 39 (3) , 241-245
Role of nitric oxide in the prevention of severe adverse events associated with blood products
- 31 December 2008
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 39 (3) , 241-245
Role of nitric oxide in the prevention of severe adverse events associated with blood products
- 1 January 2008
- Published by Taylor & Francis in Artificial Cells, Blood Substitutes, and Biotechnology
- Vol. 36 (1) , 3-18
The Effects of Preserved Red Blood Cells on the Severe Adverse Events Observed in Patients Infused with Hemoglobin Based Oxygen Carriers
The severe adverse events observed in patients who received hemoglobin based oxygen carriers (HBOCs) were associated with the Ringer's D.L lactate resuscitative solution administered and to the excipient used in the HBOCs containing Ringer's D,L lactate and the length of storage of the preserved RBC administered to the patient at the time that the HBOCs were infused. This paper reports the quality of the red blood cells preserved in the liquid state at 4°C and that of previously frozen RBCs stored at 4°C with regard to their survival, function and safety. Severe adverse events have been observed related to the length of storage of the liquid preserved RBC stored at 4°C prior to transfusion. The current methods to preserve RBC in the liquid state in additive solutions at 4°C maintain their survival and function for only 2 weeks. The freezing of red blood cells with 40% W/V glycerol and storage at −80°C allows for storage at −80°C for 10 years and following thawing, deglycerolization and storage at 4°C in the additive solution (AS-3, Nutricel) for 2 weeks with acceptable 24 hour posttransfusion survival, less than 1% hemolysis, and moderately impaired oxygen transport function with no associated adverse events. Frozen deglycerolized RBCs are leukoreduced and contain less than 5% of residual plasma and non-plasma substances. Frozen deglycerolized RBCs are the ideal RBC product to transfuse patients receiving HBOCs.
- 1 January 2008
- Published by Taylor & Francis in Artificial Cells, Blood Substitutes, and Biotechnology
- Vol. 36 (1) , 3-18
The Effects of Preserved Red Blood Cells on the Severe Adverse Events Observed in Patients Infused with Hemoglobin Based Oxygen Carriers
The severe adverse events observed in patients who received hemoglobin based oxygen carriers (HBOCs) were associated with the Ringer's D.L lactate resuscitative solution administered and to the excipient used in the HBOCs containing Ringer's D,L lactate and the length of storage of the preserved RBC administered to the patient at the time that the HBOCs were infused. This paper reports the quality of the red blood cells preserved in the liquid state at 4°C and that of previously frozen RBCs stored at 4°C with regard to their survival, function and safety. Severe adverse events have been observed related to the length of storage of the liquid preserved RBC stored at 4°C prior to transfusion. The current methods to preserve RBC in the liquid state in additive solutions at 4°C maintain their survival and function for only 2 weeks. The freezing of red blood cells with 40% W/V glycerol and storage at −80°C allows for storage at −80°C for 10 years and following thawing, deglycerolization and storage at 4°C in the additive solution (AS-3, Nutricel) for 2 weeks with acceptable 24 hour posttransfusion survival, less than 1% hemolysis, and moderately impaired oxygen transport function with no associated adverse events. Frozen deglycerolized RBCs are leukoreduced and contain less than 5% of residual plasma and non-plasma substances. Frozen deglycerolized RBCs are the ideal RBC product to transfuse patients receiving HBOCs.
- 20 September 2007
- Published by Wiley in Transfusion
- Vol. 47 (s4) , 206S-248S
Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma‐clotting proteins
Research at the Naval Blood Research Laboratory (Boston, MA) for the past four decades has focused on the preservation of red blood cells (RBCs), platelets (PLTs), and plasma‐clotting proteins to treat wounded servicemen suffering blood loss. We have studied the survival and function of fresh and preserved RBCs and PLTs and the function of fresh and frozen plasma‐clotting proteins. This report summarizes our peer‐reviewed publications on the effects of temperature, RBCs, PLTs, and plasma‐clotting proteins on the bleeding time (BT) and nonsurgical blood loss. The term nonsurgical blood loss refers to generalized, systemic bleeding that is not corrected by surgical interventions.We observed that the BT correlated with the volume of shed blood collected at the BT site and to the nonsurgical blood loss in anemic thrombocytopenic patients after cardiopulmonary bypass surgery. Many factors influence the BT, including temperature; hematocrit (Hct); PLT count; PLT size; PLT function; and the plasma‐clotting proteins factor (F)VIII, von Willebrand factor, and fibrinogen level.Our laboratory has studied temperature, Hct, PLT count, PLT size, and PLT function in studies performed in non–aspirin‐treated and aspirin‐treated volunteers, in aspirin‐treated baboons, and in anemic thrombocytopenic patients.This monograph discusses the role of RBCs and PLTs in the restoration of hemostasis, in the hope that a better understanding of the hemostatic mechanism might improve the treatment of anemic thrombocytopenic patients. Data from our studies have demonstrated that it is important to transfuse anemic thrombocytopenic patients with RBCs that have satisfactory viability and function to achieve a Hct level of 35 vol percent before transfusing viable and functional PLTs. The Biomedical Excellence for Safer Transfusion (BEST) Collaborative recommends that preserved PLTs have an in vivo recovery of 66 percent of that of fresh PLTs and a life span that is at least 50 percent that of fresh PLTs. Their recommendation does not include any indication that preserved PLTs must be able to function to reduce the BT and reduce or prevent nonsurgical blood loss.One of the hemostatic effects of RBC is to scavenge endothelial cell nitric oxide, a vasodilating agent that inhibits PLT function. In addition, endothelin may be released from endothelial cells, a potent vasoconstrictor substance,to reduce blood flow at the BT site. RBCs, like PLTs at the BT site, may provide arachidonic acid and adenosine diphosphate to stimulate the PLTs to make thromboxane, another potent vasoconstrictor substance and a PLT‐aggregating substance. At the BT site, the PLTs and RBCs are activated and phosphatidyl serine is exposed on both the PLTs and the RBCs. FVa and FXa, which generate prothrombinase activity to produce thrombin, accumulate on the PLTs and RBCs. A Hct level of 35 vol percent at the BT site minimizes shear stress and reduces nitric oxide produced by endothelial cells. The transfusion trigger for prophylactic PLT transfusion should consider both the Hct and the PLT count. The transfusion of RBCs that are both viable and functional to anemic thrombocytopenic patients may reduce the need for prophylactic leukoreduced PLTs, the alloimmunization of the patients, and the associated adverse events related to transfusion‐related acute lung injury. The cost for RBC transfusions will be significantly less than the cost for the prophylactic PLT transfusions.
- 20 September 2007
- Published by Wiley in Transfusion
- Vol. 47 (s4) , 206S-248S
Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma‐clotting proteins
Research at the Naval Blood Research Laboratory (Boston, MA) for the past four decades has focused on the preservation of red blood cells (RBCs), platelets (PLTs), and plasma‐clotting proteins to treat wounded servicemen suffering blood loss. We have studied the survival and function of fresh and preserved RBCs and PLTs and the function of fresh and frozen plasma‐clotting proteins. This report summarizes our peer‐reviewed publications on the effects of temperature, RBCs, PLTs, and plasma‐clotting proteins on the bleeding time (BT) and nonsurgical blood loss. The term nonsurgical blood loss refers to generalized, systemic bleeding that is not corrected by surgical interventions.We observed that the BT correlated with the volume of shed blood collected at the BT site and to the nonsurgical blood loss in anemic thrombocytopenic patients after cardiopulmonary bypass surgery. Many factors influence the BT, including temperature; hematocrit (Hct); PLT count; PLT size; PLT function; and the plasma‐clotting proteins factor (F)VIII, von Willebrand factor, and fibrinogen level.Our laboratory has studied temperature, Hct, PLT count, PLT size, and PLT function in studies performed in non–aspirin‐treated and aspirin‐treated volunteers, in aspirin‐treated baboons, and in anemic thrombocytopenic patients.This monograph discusses the role of RBCs and PLTs in the restoration of hemostasis, in the hope that a better understanding of the hemostatic mechanism might improve the treatment of anemic thrombocytopenic patients. Data from our studies have demonstrated that it is important to transfuse anemic thrombocytopenic patients with RBCs that have satisfactory viability and function to achieve a Hct level of 35 vol percent before transfusing viable and functional PLTs. The Biomedical Excellence for Safer Transfusion (BEST) Collaborative recommends that preserved PLTs have an in vivo recovery of 66 percent of that of fresh PLTs and a life span that is at least 50 percent that of fresh PLTs. Their recommendation does not include any indication that preserved PLTs must be able to function to reduce the BT and reduce or prevent nonsurgical blood loss.One of the hemostatic effects of RBC is to scavenge endothelial cell nitric oxide, a vasodilating agent that inhibits PLT function. In addition, endothelin may be released from endothelial cells, a potent vasoconstrictor substance,to reduce blood flow at the BT site. RBCs, like PLTs at the BT site, may provide arachidonic acid and adenosine diphosphate to stimulate the PLTs to make thromboxane, another potent vasoconstrictor substance and a PLT‐aggregating substance. At the BT site, the PLTs and RBCs are activated and phosphatidyl serine is exposed on both the PLTs and the RBCs. FVa and FXa, which generate prothrombinase activity to produce thrombin, accumulate on the PLTs and RBCs. A Hct level of 35 vol percent at the BT site minimizes shear stress and reduces nitric oxide produced by endothelial cells. The transfusion trigger for prophylactic PLT transfusion should consider both the Hct and the PLT count. The transfusion of RBCs that are both viable and functional to anemic thrombocytopenic patients may reduce the need for prophylactic leukoreduced PLTs, the alloimmunization of the patients, and the associated adverse events related to transfusion‐related acute lung injury. The cost for RBC transfusions will be significantly less than the cost for the prophylactic PLT transfusions.
- 30 April 2007
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 36 (2) , 133-137
Use of supernatant osmolality and supernatant refraction to assess the glycerol concentration in glycerolized and deglycerolized previously frozen RBC
- 30 April 2007
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 36 (2) , 133-137
Use of supernatant osmolality and supernatant refraction to assess the glycerol concentration in glycerolized and deglycerolized previously frozen RBC